Stocks and Investing
by (remove) : Sumant Kulkarni
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Sumant Kulkarni
RSSJSONXMLCSV
Wed, September 18, 2024
Fri, August 30, 2024
Thu, June 27, 2024
Thu, June 13, 2024
Tue, May 7, 2024
Tue, April 30, 2024
Tue, March 26, 2024
Thu, March 14, 2024
Tue, March 12, 2024
Wed, March 6, 2024
Tue, February 20, 2024
Fri, December 29, 2023
Mon, November 6, 2023
Fri, September 1, 2023
Tue, August 15, 2023
Thu, August 3, 2023
Mon, July 17, 2023
Mon, June 12, 2023
Wed, May 10, 2023
Wed, April 26, 2023
Tue, March 14, 2023
Tue, March 7, 2023
Fri, November 11, 2022
Wed, March 16, 2022
Mon, March 14, 2022
Mon, February 7, 2022
Wed, December 22, 2021
Tue, August 3, 2021

Sumant Kulkarni Maintained (zvra) at Strong Buy with Decreased Target to $22 on, Sep 18th, 2024


Published on 2024-10-28 14:19:47 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Zevra Therapeutics, Inc." (ZVRA) at Strong Buy with Decreased Target from $24 to $22 on, Sep 18th, 2024.

Sumant has made no other calls on ZVRA in the last 4 months.



There are 2 other peers that have a rating on ZVRA. Out of the 2 peers that are also analyzing ZVRA, 0 agree with Sumant's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Sumant


  • Louise Chen of "Cantor Fitzgerald" Reiterated at Buy on, Wednesday, August 14th, 2024
  • Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $18 on, Monday, August 5th, 2024
Contributing Sources